Skip to main content

Together we are beating cancer

Donate now

Harry Jenkins

Harry studied an integrated Master’s degree in biology at Durham University before joining Cancer Research UK in November 2018. He completed a Master’s in science communication at Imperial College London part-time alongside his work in communications teams across the charity. He worked in Cancer Research UK’s digital news team, writing news and analysis articles for their news site as well as information about their funded research for their website. He has since left Cancer Research UK.
Showing 12 out of 29 results
Close-up Of Female Doctor Injecting Male Patient With Syringe To Collect Blood Sample

A blood test capable of catching any cancer at an early stage before any symptoms may sound like science fiction but just how close are researchers to making it a reality? A blood test capable of catching any cancer at an early stage before any symptoms may sound like science fiction but just how close are researchers to making it a reality?

by Harry Jenkins | In depth | 14 April 2022

14 April 2022

Illustration showing inequalities.

We talk to Professor Sir Michael Marmot, who's been at the forefront of health inequality research for decades, to discuss what it is and how we can reduce it. We talk to Professor Sir Michael Marmot, who's been at the forefront of health inequality research for decades, to discuss what it is and how we can reduce it.

by Harry Jenkins | Analysis | 15 February 2022

15 February 2022

This entry is part 1 of 5 in the series Health inequalities

3 new cancer treatments have now been approved by the Scottish Medicines Consortium (SMC) for use on the NHS in Scotland, including 2 breast cancer treatments and 1 for lung cancer. 3 new cancer treatments have now been approved by the Scottish Medicines Consortium (SMC) for use on the NHS in Scotland, including 2 breast cancer treatments and 1 for lung cancer.

by Harry Jenkins | News | 19 January 2022

19 January 2022

Non small cell lung cancer cells stained in pleural effusion sample.

A new treatment for some people with a type of non small cell lung cancer (NSCLC) will now be routinely available on the NHS in England, following its approval by the National Institute of Health and Care Excellence (NICE). A new treatment for some people with a type of non small cell lung cancer (NSCLC) will now be routinely available on the NHS in England, following its approval by the National Institute of Health and Care Excellence (NICE).

by Harry Jenkins | News | 12 January 2022

12 January 2022

Melanoma cell. Credit: Dr Erik Sahai

The National Institute for Health and Care Excellence has recommended the use of the immunotherapy drug pembrolizumab (Keytruda) for some adults in England with a type of advanced melanoma skin cancer. The National Institute for Health and Care Excellence has recommended the use of the immunotherapy drug pembrolizumab (Keytruda) for some adults in England with a type of advanced melanoma skin cancer.

by Harry Jenkins | News | 21 December 2021

21 December 2021

Tissue from a person with high grade serous ovarian cancer. This image was taken using a powerful microscope and shows red blood cells stained in red, DNA in blue and centrosomes in
  • Health & Medicine
  • Science & Technology

6 of the biggest good news cancer stories of 2021

From promising new cancer drugs to trialling a cancer blood test, here are some of the top good news stories from 2021. From promising new cancer drugs to trialling a cancer blood test, here are some of the top good news stories from 2021.

by Harry Jenkins | Analysis | 15 December 2021

15 December 2021

Lung cancer cell

More than 600 people in England with a form of lung cancer could benefit from the innovative drug osimertinib (Tagrisso) after its approval by the National Institute for Health and Care Excellence. More than 600 people in England with a form of lung cancer could benefit from the innovative drug osimertinib (Tagrisso) after its approval by the National Institute for Health and Care Excellence.

by Harry Jenkins | News | 1 December 2021

1 December 2021

An empty hospital hallway

People who survive cancer in childhood have a higher risk of ill health as they grow older, according to new research published in The Lancet Regional Health – Europe. People who survive cancer in childhood have a higher risk of ill health as they grow older, according to new research published in The Lancet Regional Health – Europe.

by Harry Jenkins | News | 22 November 2021

22 November 2021

Lung cancer cells

Three new cancer drugs have been given the go-ahead by the Scottish Medicines Consortium (SMC) for routine use in Scotland, two for non small cell lung cancer and one for Hodgkin lymphoma, but a fourth has been rejected. Three new cancer drugs have been given the go-ahead by the Scottish Medicines Consortium (SMC) for routine use in Scotland, two for non small cell lung cancer and one for Hodgkin lymphoma, but a fourth has been rejected.

by Harry Jenkins | News | 11 November 2021

11 November 2021

Barrett's oesophagus under the microscope

Barrett’s oesophagus affects around 1 in every 100 to 200 people in the UK, and, for a small number of people, can develop into oesophageal cancer. But the origins of the condition have remained a mystery for decades, until now. Barrett’s oesophagus affects around 1 in every 100 to 200 people in the UK, and, for a small number of people, can develop into oesophageal cancer. But the origins of the condition have remained a mystery for decades, until now.

by Harry Jenkins | Analysis | 25 October 2021

25 October 2021

3D representation of oesophageal cancer

The immunotherapy drug nivolumab (Opdivo) has been made available for some people in England with oesophageal cancer, in what has been described as a ‘step change’ for people with this cancer. The immunotherapy drug nivolumab (Opdivo) has been made available for some people in England with oesophageal cancer, in what has been described as a ‘step change’ for people with this cancer.

by Harry Jenkins | News | 20 October 2021

20 October 2021

3D visualisation of thyroid cancer

The National Institute for Health and Care Excellence (NICE) has recommended the use of the drug selpercatinib (Retevmo) for some people in England with a type of advanced thyroid cancer. The National Institute for Health and Care Excellence (NICE) has recommended the use of the drug selpercatinib (Retevmo) for some people in England with a type of advanced thyroid cancer.

by Harry Jenkins | News | 1 October 2021

1 October 2021